ethanolamines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	ethanolamines	go back to main search page
Accession:	CHEBI:23981	browse the term
Synonyms:	related_synonym:	ethanolamine

show annotations for term's descendants Sort by:
Rat (826) Mouse (833) Human (836) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (826)

(-)-ephedrine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

Ephedrine inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Ephedrine inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]
Ephedrine results in increased expression of ACTA2 protein

PMID:32729338 PMID:37778983

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

apolipoprotein A1

multiple interactions

[Ephedrine co-treated with Caffeine] results in increased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

multiple interactions

[Ephedrine co-treated with Caffeine] results in decreased expression of APOA2 protein

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein B

multiple interactions

[Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C1

multiple interactions

[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein C2

multiple interactions

[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein C3

multiple interactions

[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

BCL2 associated X, apoptosis regulator

increases expression

Ephedrine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Ephedrine results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

[Caffeine co-treated with Ephedrine] results in increased cleavage of CASP3 protein
Ephedrine results in increased activity of CASP3 protein

PMID:15537744 PMID:32729338

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Ephedrine results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cadherin 1

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; Ephedrine inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

complement factor D

multiple interactions

[Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein]

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Ephedrine results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamic--pyruvic transaminase

increases expression

Ephedrine results in increased expression of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

H2A.X variant histone

multiple interactions

[Caffeine co-treated with Ephedrine] results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

interleukin 1 beta

increases expression

Ephedrine results in increased expression of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression

Ephedrine inhibits the reaction [Bleomycin results in increased secretion of IL6 protein]
Ephedrine results in increased expression of IL6 protein

PMID:32729338 PMID:37778983

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Kelch-like ECH-associated protein 1

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

keratin 8

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in decreased expression of KRT8 mRNA]; Ephedrine inhibits the reaction [Bleomycin results in decreased expression of KRT8 protein]

NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728

G

NFE2 like bZIP transcription factor 2

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NADPH oxidase 1

increases expression

Ephedrine results in increased expression of NOX1 protein

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

SMAD family member 3

increases expression

Ephedrine results in increased expression of SMAD3 mRNA; Ephedrine results in increased expression of SMAD3 protein

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

SMAD family member 7

decreases expression

Ephedrine results in decreased expression of SMAD7 protein

NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765

G

transforming growth factor, beta 1

increases expression

Ephedrine results in increased expression of TGFB1 mRNA; Ephedrine results in increased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions
increases expression

Ephedrine inhibits the reaction [Bleomycin results in increased secretion of TNF protein]
Ephedrine results in increased expression of TNF protein

PMID:32729338 PMID:37778983

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vimentin

multiple interactions

Ephedrine inhibits the reaction [Bleomycin results in increased expression of VIM mRNA]; Ephedrine inhibits the reaction [Bleomycin results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

(R)-octopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

increases activity
multiple interactions

Octopamine results in increased activity of ADRB3 protein
Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

solute carrier family 6 member 2

multiple interactions

Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions

indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

multiple interactions

Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

trace-amine-associated receptor 1

multiple interactions
increases activity

[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

PMID:17234900 PMID:19725810

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

9-[2-(phosphonomethoxy)ethyl]guanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 6

multiple interactions
increases response to substance

9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine]; Quercetin inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog]
SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine; SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

acebutolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions
increases activity

[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Acebutolol results in increased activity of ADRB1 protein]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Acebutolol results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

mitogen activated protein kinase 1

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

renin

decreases activity

Acebutolol results in decreased activity of REN protein

PMID:6110712 PMID:6118215

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

acetophenazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

acetophenazine binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

albuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases expression
multiple interactions

Albuterol results in increased expression of ABCB11 mRNA
Carvedilol inhibits the reaction [Albuterol results in increased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor beta 1

multiple interactions

Albuterol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Albuterol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]

PMID:8096834 PMID:14730417

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

decreases response to substance
increases activity
multiple interactions
increases phosphorylation
decreases expression

ADRB2 gene polymorphism results in decreased susceptibility to Albuterol
Albuterol results in increased activity of ADRB2 protein
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in decreased abundance of Potassium; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Albuterol binds to and results in increased activity of ADRB2 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Albuterol results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]
Albuterol results in increased phosphorylation of ADRB2 protein
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Hydroxyindoleacetic Acid; Albuterol binds to and results in increased activity of ADRB2 protein
Albuterol results in decreased expression of ADRB2 protein

PMID:2463453 PMID:8102213 PMID:8937731 PMID:10516654 PMID:10952688 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Albuterol binds to and results in increased activity of ADRB3 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

BCL2 associated X, apoptosis regulator

increases expression

Albuterol results in increased expression of BAX

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Albuterol results in decreased expression of BCL2

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

catalase

multiple interactions

CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 3

multiple interactions

Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

multiple interactions

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

CD44 molecule

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cyclin dependent kinase 2

increases expression

Albuterol results in increased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

increases expression

Albuterol results in increased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

creatine kinase, M-type

increases secretion

Albuterol results in increased secretion of CKM protein

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

colony stimulating factor 2

multiple interactions

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression

Albuterol results in increased expression of CYP17A1

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

[Cyproterone co-treated with Albuterol] results in decreased expression of CYP19A1

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

fibroblast growth factor 2

multiple interactions

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibronectin 1

multiple interactions

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glucose-6-phosphate dehydrogenase

increases activity

Albuterol results in increased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

insulin-like growth factor 1

affects expression

Albuterol affects the expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

decreases expression

Albuterol results in decreased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

decreases expression

Albuterol results in decreased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression

Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
Albuterol results in decreased expression of IL1B mRNA

PMID:11112151 PMID:32816093

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Albuterol results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 4

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

1-Methyl-3-isobutylxanthine promotes the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]; Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]; ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

increases expression
multiple interactions

Albuterol results in increased expression of IL6 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
[Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Theophylline co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:18362475 PMID:20388727 PMID:20519841

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

increases expression

Albuterol results in increased expression of INS; Albuterol results in increased expression of INS protein

PMID:8098220 PMID:9088585

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

low density lipoprotein receptor

affects response to substance

LDLR gene SNP affects the susceptibility to Albuterol

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

mitogen activated protein kinase 1

multiple interactions

[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:16980553 PMID:20519841

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:16980553 PMID:20519841

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myeloperoxidase

multiple interactions

[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol; Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Glutathione inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Azide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Cyanide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mechanistic target of rapamycin kinase

increases expression

Albuterol results in increased expression of MTOR mRNA

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFKB inhibitor alpha

increases expression

Albuterol results in increased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

[Beclomethasone co-treated with Albuterol] affects the localization of NR3C1 protein

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

phosphodiesterase 4A

multiple interactions

[Albuterol co-treated with Rolipram] results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

phosphodiesterase 4B

multiple interactions

[Albuterol co-treated with Rolipram] results in increased expression of PDE4B mRNA

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

phosphotyrosine interaction domain containing 1

increases expression

Albuterol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

phosphoinositide-3-kinase regulatory subunit 1

affects expression

Albuterol affects the expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

paraoxonase 1

decreases activity

Albuterol results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

PPARG coactivator 1 alpha

increases expression

Albuterol results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression

Albuterol results in increased expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

platelet-activating factor receptor

increases expression

Albuterol results in increased expression of PTAFR protein

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression

Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
Albuterol results in decreased expression of PTGS2 mRNA

PMID:11112151 PMID:32816093

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RB transcriptional corepressor 1

decreases expression
multiple interactions
increases expression

Albuterol results in decreased expression of RB1 protein
ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein]
Albuterol results in increased expression of RB1 protein

PMID:16446544 PMID:18362475

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

renin

increases expression

Albuterol results in increased expression of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 10 member 1

multiple interactions
increases expression

[Carvedilol co-treated with Albuterol] results in decreased expression of SLC10A1 protein; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 mRNA]; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 protein]
Albuterol results in increased expression of SLC10A1 mRNA; Albuterol results in increased expression of SLC10A1 protein

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

secretory leukocyte peptidase inhibitor

decreases expression

Albuterol results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

Thy-1 cell surface antigen

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

decreases secretion
multiple interactions

Albuterol results in decreased secretion of TNF protein
[Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol promotes the reaction [Theophylline inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]

PMID:8937731 PMID:10229875 PMID:20388727 PMID:20519841

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

Albuterol results in increased expression of TP53

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

uncoupling protein 1

increases expression

Albuterol results in increased expression of UCP1 protein

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

uncoupling protein 3

multiple interactions

[Albuterol co-treated with acipimox] results in decreased expression of UCP3 mRNA

NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762

anandamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ABCB1 protein results in increased export of anandamide

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]
anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein

PMID:30610963 PMID:34756920

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acyl-CoA oxidase 1

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA]

NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371

G

amyloid beta precursor protein

decreases response to substance
decreases metabolic processing
decreases abundance

anandamide results in decreased susceptibility to APP protein
APP protein results in decreased metabolism of anandamide
APP protein results in decreased abundance of anandamide

PMID:22233683 PMID:26976670

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arrestin, beta 2

multiple interactions

anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

bradykinin receptor B1

multiple interactions
decreases activity

AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

caspase 3

increases cleavage
multiple interactions

anandamide results in increased cleavage of CASP3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

increases expression

anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

glycoprotein hormones, alpha polypeptide

decreases expression

anandamide results in decreased expression of CGA mRNA

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cannabinoid receptor 1

affects activity
increases response to substance
decreases expression
affects binding
increases activity
multiple interactions

anandamide affects the activity of CNR1 protein
CNR1 protein results in increased susceptibility to anandamide
anandamide results in decreased expression of CNR1 protein
anandamide binds to CNR1 protein
anandamide results in increased activity of CNR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]
[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]

PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 More...

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

affects activity
affects binding
multiple interactions

anandamide affects the activity of CNR2 protein
anandamide binds to CNR2 protein
anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]

PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cAMP responsive element binding protein 1

multiple interactions
decreases phosphorylation

anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]
anandamide results in decreased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

decreases abundance

CRH protein results in decreased abundance of anandamide

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions
increases metabolic processing

cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]

PMID:21949157 PMID:26513129 PMID:29441458

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

anandamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

endogenous retrovirus group FRD member 1, envelope

decreases expression

anandamide results in decreased expression of ERVFRD-1 mRNA

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

coagulation factor III, tissue factor

multiple interactions
increases expression

anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
anandamide results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid amide hydrolase

increases degradation
increases response to substance
decreases metabolic processing
multiple interactions
affects expression

FAAH results in increased degradation of anandamide
FAAH gene mutant form results in increased susceptibility to anandamide
FAAH gene mutant form results in decreased metabolism of anandamide
FAAH protein results in increased degradation of anandamide
[Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide]
anandamide affects the expression of FAAH protein
[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]

PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 More...

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 1

multiple interactions
affects abundance
affects binding

11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein]
FABP1 protein affects the abundance of anandamide
FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]

PMID:29414765 PMID:30232874

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein]
anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein

PMID:9748483 PMID:15601931 PMID:19515121

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

interferon gamma

multiple interactions

anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

increases expression

anandamide results in increased expression of IGF1 protein

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 12B

multiple interactions

[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]

PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases abundance
multiple interactions
decreases activity
decreases transport

LEP protein results in decreased abundance of anandamide
Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide]
LEP protein results in decreased activity of anandamide
LEP protein results in decreased transport of anandamide

PMID:16154199 PMID:29967158

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

increases expression

anandamide results in increased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 3

increases expression

anandamide results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions
increases expression

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nitric oxide synthase 2

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

PMID:11891798 PMID:15748152

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

increases cleavage

anandamide results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

peroxisome proliferator activated receptor alpha

multiple interactions

anandamide binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing

[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide
anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein
PTGS2 results in increased metabolism of anandamide
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]

PMID:16330497 PMID:17245358 PMID:20702753

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin P

multiple interactions
increases expression

anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein]
anandamide results in increased expression of SELP protein

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

anandamide results in increased expression of TIMP1 mRNA
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases abundance

anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]
TNF protein results in increased abundance of anandamide
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]

PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
increases response to substance
increases activity
affects response to substance
affects binding

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]
TRPV1 protein results in increased susceptibility to anandamide
anandamide results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein]
anandamide binds to TRPV1 protein

PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 More...

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vascular endothelial growth factor A

multiple interactions

anandamide results in decreased expression of and results in decreased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

atenolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Atenolol results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor alpha 2A

affects response to substance

ADRA2A gene SNP affects the susceptibility to Atenolol

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

decreases activity
multiple interactions
affects binding
affects response to substance
decreases expression

Atenolol results in decreased activity of ADRB1 protein
Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein]
Atenolol binds to ADRB1 protein
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]
ADRB1 protein polymorphism affects the susceptibility to Atenolol
Atenolol results in decreased expression of ADRB1 mRNA

PMID:1389726 PMID:2462161 PMID:2897299 PMID:8102213 PMID:8386603 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

increases expression
affects binding
multiple interactions

Atenolol results in increased expression of ADRB2 protein
Atenolol binds to ADRB2 protein
Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]
[Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]

PMID:2462161 PMID:6093157 PMID:9593075 PMID:11425575 PMID:11483288 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Atenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

angiotensinogen

affects response to substance
decreases expression

AGT gene SNP affects the susceptibility to Atenolol
Atenolol results in decreased expression of AGT protein

PMID:14639093 PMID:14700505

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

amylase 2a3

multiple interactions

Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Cisplatin results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Lithium Chloride results in increased secretion of and results in increased activity of AMY1A protein]

NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532

G

apolipoprotein A1

decreases expression

Atenolol results in decreased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Atenolol results in decreased expression of APOA2 protein

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein B

increases expression

Atenolol results in increased expression of APOB; Atenolol results in increased expression of APOB protein

PMID:1928808 PMID:2193493

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

activating transcription factor 1

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

beta-2 microglobulin

decreases expression

Atenolol results in decreased expression of B2M protein

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

bradykinin receptor B2

affects response to substance

BDKRB2 exon polymorphism affects the susceptibility to Atenolol

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

calcium voltage-gated channel subunit alpha1 C

increases response to substance

CACNA1C gene polymorphism results in increased susceptibility to Atenolol

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

caspase 3

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Atenolol promotes the reaction [Quercetin inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Quercetin promotes the reaction [Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]

PMID:2575990 PMID:22391854

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase 1

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in increased expression of CDK1 mRNA]

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cAMP responsive element binding protein 1

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

endothelin 1

affects response to substance

EDN1 gene polymorphism affects the susceptibility to Atenolol

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor receptor

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

Fas cell surface death receptor

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FKBP prolyl isomerase 1B

multiple interactions

Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein]

NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653

G

FKBP prolyl isomerase 5

decreases expression

Atenolol results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

glucose-6-phosphate dehydrogenase

multiple interactions

Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

gap junction protein, alpha 1

increases expression

Atenolol results in increased expression of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 4

increases expression

Atenolol results in increased expression of GJA4 protein

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

G protein-coupled receptor kinase 2

decreases expression

Atenolol results in decreased expression of GRK2 mRNA; Atenolol results in decreased expression of GRK2 protein

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

insulin 2

multiple interactions

Atenolol inhibits the reaction [Terbutaline results in increased expression of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 2

affects response to substance

KCNJ2 gene affects the susceptibility to Atenolol

NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445

G

potassium voltage-gated channel subfamily Q member 1

affects response to substance

KCNQ1 gene affects the susceptibility to Atenolol

NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669

G

lipase C, hepatic type

multiple interactions

LIPC gene SNP affects the susceptibility to and affects the metabolism of Atenolol

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

mitogen activated protein kinase 1

multiple interactions

[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]

PMID:16671086 PMID:17003101 PMID:17925438

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]

PMID:16671086 PMID:17003101 PMID:17925438

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nitric oxide synthase 2

multiple interactions

Atenolol inhibits the reaction [Carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

decreases expression

Atenolol results in decreased expression of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

multiple interactions
decreases expression
increases expression

[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA
Atenolol results in decreased expression of NPPB mRNA
Atenolol results in increased expression of NPPB protein

PMID:15969258 PMID:18192850

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

phospholipase A2 group IVC

multiple interactions

PLA2G4C gene SNP affects the susceptibility to and affects the metabolism of Atenolol

NCBI chr 1:74,237,714...74,275,757
Ensembl chr 1:74,236,211...74,274,656

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

renin

multiple interactions
decreases expression
decreases activity

[aliskiren co-treated with Atenolol] results in decreased activity of REN protein; [Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein
Atenolol results in decreased expression of REN protein
Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]; Atenolol inhibits the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein]
Atenolol results in decreased activity of REN protein

PMID:3142437 PMID:3333524 PMID:9300315 PMID:14639093 PMID:18957387

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ryanodine receptor 2

increases activity
multiple interactions

Atenolol results in increased activity of RYR2 protein
Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein]

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

solute carrier family 19 member 1

decreases expression

Atenolol results in decreased expression of SLC19A1 mRNA

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 22 member 1

multiple interactions

Atenolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 6 member 8

decreases expression

Atenolol results in decreased expression of SLC6A8 mRNA

NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979

G

solute carrier organic anion transporter family, member 4C1

increases expression

Atenolol results in increased expression of SLCO4C1 mRNA

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715

G

small nucleolar RNA, H/ACA box 49

increases expression

Atenolol results in increased expression of SNORA49 mRNA

NCBI chr12:45,970,884...45,971,016
Ensembl chr12:45,970,884...45,971,016

G

small nuclear ribonucleoprotein polypeptide N

increases expression

Atenolol results in increased expression of SNRPN mRNA

NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634

G

superoxide dismutase 1

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]
Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]

PMID:2575990 PMID:11163531

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]
Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]

PMID:2575990 PMID:11163531

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transient receptor potential cation channel, subfamily A, member 1

decreases response to substance

TRPA1 gene mutant form results in decreased susceptibility to Atenolol

NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570

G

thioredoxin 1

increases expression

Atenolol results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

bambuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

bambuterol results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adrenoceptor beta 2

increases activity

bambuterol results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

butyrylcholinesterase

decreases activity

bambuterol results in decreased activity of BCHE protein

PMID:15652380 PMID:18582854 PMID:18977317

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

bitolterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

multiple interactions
increases activity

ICI 118551 inhibits the reaction [bitolterol results in increased activity of ADRB2 protein]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

chloroprocaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

chloroprocaine results in increased expression of BAX protein
LINC00494 inhibits the reaction [chloroprocaine results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

cyclin D1

decreases expression
multiple interactions

chloroprocaine results in decreased expression of CCND1 protein
LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

mediator complex subunit 19

decreases expression
multiple interactions

chloroprocaine results in decreased expression of MED19 mRNA; chloroprocaine results in decreased expression of MED19 protein
LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 mRNA]; LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 protein]

NCBI chr 3:69,762,138...69,772,661
Ensembl chr 3:69,762,166...69,772,036

G

proliferating cell nuclear antigen

decreases expression
multiple interactions

chloroprocaine results in decreased expression of PCNA protein
LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

clenbuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase medium chain

increases expression

Clenbuterol results in increased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

adrenoceptor beta 2

multiple interactions
increases activity

[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]
Clenbuterol results in increased activity of ADRB2 protein

PMID:16007677 PMID:18552870 PMID:34601065

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Clenbuterol binds to and results in increased activity of ADRB3 protein

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

AKT serine/threonine kinase 1

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

estrogen related receptor, alpha

increases expression

Clenbuterol results in increased expression of ESRRA mRNA

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

glutamate decarboxylase 1

multiple interactions

Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]; Clenbuterol inhibits the reaction [Reserpine results in increased expression of GAD1 mRNA]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]]

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

interleukin 10

multiple interactions
affects expression

Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein]
Clenbuterol affects the expression of IL10 protein

PMID:15021963 PMID:15502056

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

increases expression

Clenbuterol results in increased expression of IL18 mRNA; Clenbuterol results in increased expression of IL18 protein

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

NFKB inhibitor alpha

multiple interactions

Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

ornithine decarboxylase 1

multiple interactions
increases stability
increases activity

Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Propranolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]
Clenbuterol results in increased stability of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

pyruvate dehydrogenase kinase 4

increases expression

Clenbuterol results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Clenbuterol results in increased expression of PPARGC1A mRNA
Propranolol inhibits the reaction [Clenbuterol results in increased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Clenbuterol affects the reaction [Lipopolysaccharides affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

transcription factor A, mitochondrial

increases expression

Clenbuterol results in increased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

tumor necrosis factor

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

PMID:15021963 PMID:15710352

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

uncoupling protein 1

increases expression

Clenbuterol results in increased expression of UCP1 protein

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

clorprenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

increases activity

clorprenaline results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

solute carrier family 22 member 2

multiple interactions

clorprenaline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

dicyclomine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

diethanolamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated agonist of cell death

decreases expression

diethanolamine results in decreased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

decreases expression

diethanolamine results in decreased expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

calbindin 1

increases expression

diethanolamine results in increased expression of CALB1 mRNA

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

caspase 3

decreases expression
increases activity

diethanolamine results in decreased expression of CASP3 mRNA
diethanolamine results in increased activity of CASP3 protein

PMID:16014740 PMID:18948303

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D2

increases expression

diethanolamine results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E1

increases expression

diethanolamine results in increased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin-dependent kinase inhibitor 1A

decreases expression

diethanolamine results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression

diethanolamine results in decreased expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

E2F transcription factor 1

increases expression

diethanolamine results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

interleukin 2

multiple interactions

[diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

ribonucleotide reductase regulatory TP53 inducible subunit M2B

increases expression

diethanolamine results in increased expression of RRM2B mRNA

NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633

G

tumor protein p53

decreases expression

diethanolamine results in decreased expression of TRP53 mRNA
diethanolamine results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

Wnt family member 1

increases expression

diethanolamine results in increased expression of WNT1 mRNA

NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651

esmolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

decreases activity

esmolol results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

bone morphogenetic protein 6

increases expression

esmolol results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

epiregulin

increases expression

esmolol results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

heme oxygenase 1

multiple interactions

esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 alpha

increases expression

esmolol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

esmolol results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

esmolol results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

esmolol results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

phosphotyrosine interaction domain containing 1

increases expression

esmolol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

prostaglandin-endoperoxide synthase 2

increases expression

esmolol results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

renin

multiple interactions

esmolol inhibits the reaction [Nitroprusside results in increased activity of REN protein]

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

secretory leukocyte peptidase inhibitor

increases expression

esmolol results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

TNF alpha induced protein 6

increases expression

esmolol results in increased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

etanidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

affects response to substance

CAT protein affects the susceptibility to Etanidazole

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

ethambutol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

angiotensin converting enzyme 2

increases expression

Ethambutol results in increased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

bone morphogenetic protein 6

decreases expression

Ethambutol results in decreased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in decreased activity of CAT protein

PMID:34118364 PMID:36878459

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

affects expression

Ethambutol affects the expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

affects expression

Ethambutol affects the expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cathepsin D

multiple interactions

Ethambutol results in increased expression of and affects the localization of CTSD protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of and affects the localization of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Ethambutol results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Ethambutol results in decreased activity of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

Ethambutol results in decreased activity of CYP2D6 protein

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions

Ethambutol results in decreased activity of CYP2E1 protein
Ethambutol results in increased expression of CYP2E1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Ethambutol results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

PMID:24910189 PMID:27334974 PMID:27919644

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

glutamic--pyruvic transaminase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:35835356 PMID:36878459

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

granzyme B

increases secretion

Ethambutol results in increased secretion of GZMB protein

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

interferon gamma

increases secretion

Ethambutol results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

decreases expression

Ethambutol results in decreased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

increases secretion

Ethambutol results in increased secretion of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 alpha

increases expression

Ethambutol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

decreases expression

Ethambutol results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression

Ethambutol results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

Ethambutol results in increased expression of LAMP2 protein
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of LAMP2 protein]

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

leptin

decreases expression

Ethambutol results in decreased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Ethambutol results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

myeloperoxidase

multiple interactions

[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

phosphotyrosine interaction domain containing 1

increases expression

Ethambutol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

solute carrier family 10 member 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 7 member 11

increases expression
multiple interactions

Ethambutol results in increased expression of SLC7A11 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

PMID:32816093 PMID:36878459

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Ethambutol results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

ethanolamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apolipoprotein B

multiple interactions

[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

multiple interactions

[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

epidermal growth factor

increases activity

Ethanolamine results in increased activity of EGF protein

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

fibroblast growth factor 1

increases activity

Ethanolamine results in increased activity of FGF1 protein

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

pancreatic lipase related protein 2

increases metabolic processing

PNLIPRP2 protein results in increased metabolism of Ethanolamine

NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434

indinavir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

Indinavir results in decreased activity of ABCB11 protein
Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

PMID:20829430 PMID:23956101 PMID:24014644 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

acetylcholinesterase

multiple interactions

Indinavir inhibits the reaction [Celecoxib results in increased activity of ACHE protein]; Indinavir inhibits the reaction [Streptozocin results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adiponectin, C1Q and collagen domain containing

decreases expression
multiple interactions

Indinavir results in decreased expression of ADIPOQ protein
Indinavir results in decreased expression of ADIPOQ mRNA; Indinavir results in decreased expression of ADIPOQ protein
diphenyleneiodonium inhibits the reaction [Indinavir results in decreased expression of ADIPOQ protein]; Indinavir inhibits the reaction [ADIPOQ protein modified form results in increased uptake of Deoxyglucose]

PMID:15865214 PMID:17668557 PMID:29991592

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AE binding protein 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA

NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, biomineralization associated

multiple interactions

AGN 193109 inhibits the reaction [Indinavir promotes the reaction [Tretinoin results in increased expression of ALPL protein]]; Indinavir promotes the reaction [Tretinoin results in increased expression of ALPL protein]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

apolipoprotein B

decreases secretion

Indinavir results in decreased secretion of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C3

decreases secretion
decreases expression

Indinavir results in decreased secretion of APOC3 protein
Indinavir results in decreased expression of APOC3 mRNA

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

cAMP regulated phosphoprotein 21

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA

NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297

G

acid sensing ion channel subunit 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA

NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

complement C1r

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA

NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484

G

complement C3a receptor 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA

NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

Indinavir results in increased expression of CCL2 protein
diphenyleneiodonium inhibits the reaction [Indinavir results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression

Indinavir results in increased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

CD36 molecule

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell death-inducing DFFA-like effector c

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

chloride voltage-gated channel 3

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119

G

C-reactive protein

decreases expression

Indinavir results in decreased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

decorin

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

DNA-damage inducible transcript 3

increases expression

Indinavir results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dual specificity phosphatase 3

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA

NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases expression

Indinavir results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

ELOVL fatty acid elongase 3

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA

NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115

G

estrogen receptor 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

ETS variant transcription factor 6

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA

NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992

G

fatty acid desaturase 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas apoptotic inhibitory molecule

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA

NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562

G

fatty acid synthase

increases expression
multiple interactions

Indinavir results in increased expression of FASN mRNA
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

G0/G1switch 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA

NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451

G

glucosidase, alpha; neutral C

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA

NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241

G

guanylate cyclase 1 soluble subunit beta 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA

NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hyperpolarization-activated cyclic nucleotide-gated potassium channel 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA

NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774

G

histone cluster 1 H4 family member B

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA

NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370

G

heat shock protein family A (Hsp70) member 5

increases expression

Indinavir results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

IKAROS family zinc finger 4

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA

NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341

G

interleukin 6

multiple interactions
increases expression

diphenyleneiodonium inhibits the reaction [Indinavir results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

kelch-like family member 28

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA

NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164

G

laminin subunit gamma 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

leptin

multiple interactions
decreases expression

diphenyleneiodonium inhibits the reaction [Indinavir results in decreased expression of LEP protein]
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA

PMID:16931933 PMID:17668557

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipoprotein lipase

decreases activity
multiple interactions
increases expression

Indinavir results in decreased activity of LPL protein
[Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA
Indinavir results in increased expression of LPL mRNA

PMID:11741158 PMID:11786383

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

malic enzyme 1

multiple interactions

[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

MGAT4 family, member C

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA

NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571

G

matrix metallopeptidase 2

multiple interactions

Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 mRNA]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions

Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

melanocortin 2 receptor accessory protein

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA

NCBI chr11:29,991,974...30,003,024
Ensembl chr11:29,992,034...30,003,024

G

microsomal triglyceride transfer protein

decreases expression

Indinavir results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

myogenic differentiation 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA

NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554

G

nucleosome assembly protein 1-like 5

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA

NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654

G

nocturnin

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA

NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400

G

natriuretic peptide A

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NPPA mRNA

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

nuclear respiratory factor 1

increases expression

Indinavir results in increased expression of NRF1 mRNA

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

nucleoporin 210

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA

NCBI chr 4:123,511,558...123,609,874
Ensembl chr 4:123,511,559...123,609,874

G

ornithine decarboxylase antizyme 3

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA

NCBI chr 2:182,073,212...182,076,147
Ensembl chr 2:182,073,215...182,082,399

G

prolyl 4-hydroxylase subunit beta

increases expression

Indinavir results in increased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

protocadherin related 15

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA

NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

PHD finger protein 6

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA

NCBI chr X:132,656,658...132,699,720
Ensembl chr X:132,656,672...132,699,127

G

p53-induced death domain protein 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA

NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699

G

piwi-like RNA-mediated gene silencing 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA

NCBI chr15:45,431,402...45,498,034
Ensembl chr15:45,431,703...45,497,702

G

porcupine O-acyltransferase

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA

NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481

G

POU class 5 homeobox 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator-activated receptor gamma

decreases expression

Indinavir results in decreased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PR/SET domain 1

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA

NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488

G

receptor accessory protein 6

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA

NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597

G

ring finger protein 151

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA

NCBI chr10:13,742,682...13,747,192
Ensembl chr10:13,742,682...13,745,000

G

RPA interacting protein

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA

NCBI chr10:55,692,410...55,699,910
Ensembl chr10:55,692,417...55,699,933

G

S100 calcium binding protein A8

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

solute carrier family 25 member 19

multiple interactions

SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir]

NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447

G

solute carrier family 2 member 4

multiple interactions

[Indinavir results in decreased activity of SLC2A4 protein] inhibits the reaction [resveratrol results in increased uptake of Deoxyglucose]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

serine peptidase inhibitor, Kazal type 5

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA

NCBI chr18:36,264,452...36,333,143
Ensembl chr18:36,264,452...36,332,185

G

transcription factor AP-2 alpha

decreases expression

Indinavir results in decreased expression of TFAP2A mRNA

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

TIMP metallopeptidase inhibitor 2

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

tumor necrosis factor

multiple interactions

Indinavir inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tripartite motif-containing 42

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA

NCBI chr 8:97,902,349...97,923,268
Ensembl chr 8:97,902,353...97,923,268

G

uncoupling protein 1

decreases expression

Indinavir results in decreased expression of UCP1 mRNA

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

Wnt family member 10A

multiple interactions

[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA

NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400

L-isoprenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation

Isoproterenol increases phosphorylation of Akt1 protein in the heart

RGD

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

lysophosphatidylethanolamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 3

multiple interactions

lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of BIRC3 protein]

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

caspase 3

multiple interactions

lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of CFLAR mRNA]
lysophosphatidylethanolamine analog results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
lysophosphatidylethanolamine analog results in increased expression of CFLAR mRNA; lysophosphatidylethanolamine analog results in increased expression of CFLAR protein

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

glycogen synthase kinase 3 beta

multiple interactions

[lysophosphatidylethanolamine analog co-treated with cobaltous chloride] results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
increases expression

lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of and results in increased degradation of MCL1 protein]
lysophosphatidylethanolamine analog results in increased expression of MCL1 protein
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine; [NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine analog

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

poly (ADP-ribose) polymerase 1

multiple interactions

lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

tumor protein p53

multiple interactions

[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

metaproterenol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

decreases expression
increases activity
affects expression
increases phosphorylation
multiple interactions

Metaproterenol results in decreased expression of ADRB2 protein
Metaproterenol results in increased activity of ADRB2 protein
Metaproterenol affects the expression of ADRB2 mRNA
Metaproterenol results in increased phosphorylation of ADRB2 protein
[Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Metaproterenol binds to and results in increased activity of ADRB2 protein

PMID:16980553 PMID:24705868 PMID:34601065

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

BCL2 associated X, apoptosis regulator

increases expression

Metaproterenol results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

branched chain amino acid transaminase 1

increases expression

Metaproterenol results in increased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

BCL2, apoptosis regulator

decreases expression

Metaproterenol results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2 interacting protein 1

increases expression

Metaproterenol results in increased expression of BNIP1 protein

NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157

G

clusterin

increases expression

Metaproterenol results in increased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

fatty acid binding protein 3

increases expression

Metaproterenol results in increased expression of FABP3 protein

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

four and a half LIM domains 1

increases expression

Metaproterenol results in increased expression of FHL1 mRNA

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

interleukin 1 alpha

decreases expression

Metaproterenol results in decreased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

decreases expression

Metaproterenol results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

LIM and cysteine-rich domains 1

increases expression

Metaproterenol results in increased expression of LMCD1 mRNA

NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046

G

phosphotyrosine interaction domain containing 1

increases expression

Metaproterenol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

prostaglandin-endoperoxide synthase 2

decreases expression

Metaproterenol results in decreased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Rho family GTPase 1

increases expression

Metaproterenol results in increased expression of RND1 mRNA

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

serpin family E member 1

increases expression

Metaproterenol results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

secretory leukocyte peptidase inhibitor

increases expression

Metaproterenol results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

secreted phosphoprotein 1

increases expression

Metaproterenol results in increased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

transforming growth factor, beta 2

increases expression

Metaproterenol results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

TIMP metallopeptidase inhibitor 1

increases expression

Metaproterenol results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

troponin I3, cardiac type

increases expression

Metaproterenol results in increased expression of TNNI3 protein

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

troponin T2, cardiac type

increases expression

Metaproterenol results in increased expression of TNNT2 protein

NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388

mirabegron

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in decreased secretion of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

caspase 3

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

glutathione S-transferase mu 1

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in decreased expression of GSTM1 protein]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

myeloperoxidase

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

toll-like receptor 4

multiple interactions

mirabegron inhibits the reaction [Acetic Acid results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

N,N-dimethylethanolamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

Deanol inhibits the reaction [Metribolone results in increased activity of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

N-methylethanolamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

histamine receptor H3

multiple interactions

N-methylaminoethanol binds to and results in decreased activity of HRH3 protein

NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642

octopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

increases activity
multiple interactions

Octopamine results in increased activity of ADRB3 protein
Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

solute carrier family 6 member 2

multiple interactions

Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions

indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

multiple interactions

Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

trace-amine-associated receptor 1

multiple interactions
increases activity

[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]

PMID:17234900 PMID:19725810

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

oleoyl ethanolamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ABCB1 protein results in increased export of N-oleoylethanolamine

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

peroxisome proliferator activated receptor alpha

increases response to substance
multiple interactions

PPARA results in increased susceptibility to N-oleoylethanolamine
N-oleoylethanolamine binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

decreases expression

N-oleoylethanolamine results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

olomoucine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin-dependent kinase 1

multiple interactions

olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; olomoucine inhibits the reaction [TP53 results in decreased phosphorylation of CDK1 protein]

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases activity
multiple interactions

olomoucine results in decreased activity of CDK2 protein
olomoucine inhibits the reaction [CDK2 protein results in increased phosphorylation of TPI1 protein]

PMID:12387751 PMID:15026556 PMID:20149834

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

RB transcriptional corepressor 1

increases expression

olomoucine results in increased expression of RB1 mRNA; olomoucine results in increased expression of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

Sp1 transcription factor

increases expression

olomoucine results in increased expression of SP1 mRNA; olomoucine results in increased expression of SP1 protein

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

tumor protein p53

multiple interactions

olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; olomoucine inhibits the reaction [TP53 results in decreased phosphorylation of CDK1 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

multiple interactions

olomoucine inhibits the reaction [CDK2 protein results in increased phosphorylation of TPI1 protein]

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

oxybuprocaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

increases expression

benoxinate results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

BCL2 associated X, apoptosis regulator

increases expression

benoxinate results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl2-like 1

decreases expression

benoxinate results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 2

increases activity

benoxinate results in increased activity of CASP2 protein

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

increases activity

benoxinate results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

benoxinate results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

potassium voltage-gated channel subfamily H member 2

decreases activity

benoxinate results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

nuclear receptor subfamily 1, group I, member 2

increases activity

benoxinate results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

solute carrier family 22 member 2

multiple interactions

benoxinate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

palmitoyl ethanolamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ABCB1 protein results in increased export of palmidrol

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

apolipoprotein B

affects folding

palmidrol affects the folding of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

aquaporin 3 (Gill blood group)

multiple interactions

[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 4

affects expression

palmidrol affects the expression of AQP4 mRNA

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

claudin 3

multiple interactions
decreases expression

[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA
palmidrol results in decreased expression of CLDN3 mRNA

NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001

G

claudin 5

decreases expression

palmidrol results in decreased expression of CLDN5 mRNA

NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992

G

cannabinoid receptor 1

multiple interactions

[rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

affects binding
multiple interactions

palmidrol binds to CNR2 protein
[SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog

PMID:10617657 PMID:10688601 PMID:17558434

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

glutathione S-transferase alpha 1

multiple interactions

palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

interferon gamma

multiple interactions

[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

[hempseed oil co-treated with palmidrol] results in decreased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 6

multiple interactions

[hempseed oil co-treated with palmidrol] results in decreased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lipocalin 2

multiple interactions

palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein]

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

peroxisome proliferator activated receptor alpha

multiple interactions
affects localization

[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]
palmidrol affects the localization of PPARA protein

PMID:17558434 PMID:31787870

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

tumor necrosis factor

multiple interactions

[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

penbutolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

decreases activity

Penbutolol results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

bone morphogenetic protein 6

increases expression

Penbutolol results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

epiregulin

increases expression

Penbutolol results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

interleukin 1 alpha

increases expression

Penbutolol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

Penbutolol results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Penbutolol results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Penbutolol results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

phosphotyrosine interaction domain containing 1

increases expression

Penbutolol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

prostaglandin-endoperoxide synthase 2

increases expression

Penbutolol results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

solute carrier family 7 member 11

increases expression

Penbutolol results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Penbutolol results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

perphenazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carboxylesterase 1D

multiple interactions

Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-nitrophenyl acetate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Perphenazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

follicle stimulating hormone subunit beta

decreases expression

Perphenazine results in decreased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

Perphenazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Perphenazine results in decreased activity of KCNH2 protein

PMID:21158687 PMID:28551711

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

luteinizing hormone subunit beta

decreases expression

Perphenazine results in decreased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

prolactin

increases expression

Perphenazine results in increased expression of PRL protein

PMID:6770916 PMID:7262630 PMID:17335319

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

solute carrier family 22 member 2

multiple interactions

Perphenazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

troponin I3, cardiac type

increases expression

Perphenazine results in increased expression of TNNI3 protein

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

phenylephrine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 9

decreases expression

Phenylephrine results in decreased expression of ABCC9 mRNA

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356

G

abhydrolase domain containing 2, acylglycerol lipase

increases expression

Phenylephrine results in increased expression of ABHD2 mRNA

NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation
affects response to substance

ABL1 protein affects the reaction [Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]]; ABL1 protein affects the reaction [Phenylephrine promotes the reaction [CRK protein binds to WASL protein]]; ABL1 protein affects the reaction [Phenylephrine results in increased phosphorylation of BCAR1 protein]
Phenylephrine results in increased phosphorylation of ABL1 protein
ABL1 protein affects the susceptibility to Phenylephrine

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

ankyrin repeat and BTB domain containing 3

decreases expression

Phenylephrine results in decreased expression of ABTB3 mRNA

NCBI chr 7:18,035,151...18,310,718
Ensembl chr 7:18,036,083...18,310,834

G

acyl-CoA dehydrogenase medium chain

multiple interactions
decreases expression

AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of ACADM mRNA]; dorsomorphin promotes the reaction [Phenylephrine results in decreased expression of ACADM mRNA]

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acetyl-CoA acetyltransferase 2

increases expression

Phenylephrine results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

angiotensin I converting enzyme

affects response to substance

ACE protein affects the susceptibility to Phenylephrine

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA thioesterase 2

increases expression

Phenylephrine results in increased expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

actin, alpha 1, skeletal muscle

multiple interactions
increases expression

[Phenylephrine co-treated with ADRA1B protein] results in increased expression of ACTA1 protein; [Phenylephrine co-treated with Isoproterenol] results in increased expression of ACTA1 mRNA; [Phenylephrine results in increased activity of ITPR2 protein] which results in increased expression of ACTA1 mRNA; ANGPT1 protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; EGR1 protein affects the reaction [[Phenylephrine co-treated with Isoproterenol] results in increased expression of ACTA1 mRNA]
MAPK8IP1 protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; RGS2 protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; S100A6 protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; S100B protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; TGFB1I1 protein promotes the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]

PMID:10642269 PMID:10710348 PMID:11230109 PMID:11499749 PMID:11513749 More...

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

MYOCD protein affects the reaction [Phenylephrine results in increased expression of ACTA2 mRNA]

PMID:16556869 PMID:18158353

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin related protein 3

increases expression

Phenylephrine results in increased expression of ACTR3 mRNA

NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124

G

ADAM metallopeptidase domain 17

multiple interactions

ADAM17 protein affects the reaction [Phenylephrine results in increased cleavage of and results in increased secretion of EGF protein]; ADAM17 protein affects the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; ADAM17 protein affects the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

adenylate cyclase 5

increases response to substance

ADCY5 protein results in increased susceptibility to Phenylephrine

NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974

G

alcohol dehydrogenase, iron containing, 1

decreases expression

Phenylephrine results in decreased expression of ADHFE1 mRNA

NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517

G

adrenomedullin

multiple interactions
decreases response to substance
decreases expression
decreases secretion
increases expression

[Phenylephrine co-treated with Isoproterenol] results in increased expression of ADM mRNA; [Phenylephrine co-treated with Isoproterenol] results in increased expression of ADM protein; ADM protein inhibits the reaction [Phenylephrine results in increased expression of MYL2 mRNA]; ADM protein inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
ADM protein results in decreased susceptibility to Phenylephrine
Phenylephrine results in decreased expression of ADM mRNA
Phenylephrine results in decreased secretion of ADM protein
Phenylephrine results in increased expression of ADM mRNA; Phenylephrine results in increased expression of ADM protein

PMID:11470465 PMID:15370692 PMID:17250927

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A1 receptor

multiple interactions
increases expression

1,3-dipropyl-8-cyclopentylxanthine inhibits the reaction [N(6)-cyclopentyladenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA1 mRNA]]; 1,3-dipropyl-8-cyclopentylxanthine inhibits the reaction [N(6)-cyclopentyladenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA1 protein]]; ADORA1 protein affects the reaction [Phenylephrine results in increased expression of NPPA mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA1 mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA1 protein]; N(6)-cyclopentyladenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA1 mRNA]; N(6)-cyclopentyladenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA1 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA1 protein]
Phenylephrine results in increased expression of ADORA1 mRNA; Phenylephrine results in increased expression of ADORA1 protein

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

multiple interactions
increases expression

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]]; ADORA2A protein affects the reaction [Phenylephrine results in increased expression of NPPA mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]
Phenylephrine results in increased expression of ADORA2A mRNA; Phenylephrine results in increased expression of ADORA2A protein

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

adenosine A3 receptor

multiple interactions
increases expression

2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; ADORA3 protein affects the reaction [Phenylephrine results in increased expression of NPPA mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; alpha,beta-methyleneadenosine 5'-diphosphate inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]; Prazosin inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]
Phenylephrine results in increased expression of ADORA3 mRNA; Phenylephrine results in increased expression of ADORA3 protein

NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357

G

ADP-ribosylhydrolase like 1

increases expression

Phenylephrine results in increased expression of ADPRHL1 mRNA

NCBI chr16:76,283,186...76,315,075
Ensembl chr16:76,283,103...76,354,440

G

adrenoceptor alpha 1A

multiple interactions
increases activity
affects activity
increases response to substance
affects binding
affects response to substance

5-methylurapidil inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium]; [KCND3 protein co-treated with ADRA1A protein] affects the susceptibility to Phenylephrine; [Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the abundance of Phosphatidylinositol 4,5-Diphosphate; [Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium; [Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein; [Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein; [Phenylephrine results in increased activity of ADRA1A protein] which affects the transport of Potassium; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; KT 5720 inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in decreased transport of Potassium]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Phenylephrine binds to and results in increased activity of ADRA1A protein; Phenylephrine results in decreased activity of [KCND3 protein alternative form co-treated with ADRA1A protein]; Prazosin inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in decreased transport of Potassium]; Ro 32-0432 inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in decreased transport of Potassium]
8-Hydroxy-2-(di-n-propylamino)tetralin promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]; [Phenylephrine affects the activity of ADRA1A protein] which affects the transport of Potassium; [Phenylephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of EIF4EBP1 protein; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of MTOR protein; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of RPS6KB1 protein; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased transport of Glucose; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of EIF4EBP1 protein]; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of MTOR protein]; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of RPS6KB1 protein]; Ethanol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of EIF4EBP1 protein]; Ethanol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of MTOR protein]; Ethanol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of RPS6KB1 protein]; GR 127935 promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]; Granisetron promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]; Lisuride promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]; Methysergide promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]; Phenylephrine binds to and results in increased activity of ADRA1A protein
ADRA1A protein results in increased susceptibility to Phenylephrine
Phenylephrine binds to ADRA1A protein
ADRA1A protein affects the susceptibility to Phenylephrine

PMID:8183249 PMID:11709419 PMID:12935885 PMID:15306222 PMID:15365637 More...

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1B

affects response to substance
increases response to substance
multiple interactions
decreases expression
increases activity

ADRA1B protein affects the susceptibility to Phenylephrine
ADRA1B protein results in increased susceptibility to Phenylephrine
[Phenylephrine co-treated with ADRA1B protein] results in decreased expression of ATP2A2 protein; [Phenylephrine co-treated with ADRA1B protein] results in decreased expression of NPY protein; [Phenylephrine co-treated with ADRA1B protein] results in increased expression of ACTA1 protein; [Phenylephrine co-treated with ADRA1B protein] results in increased expression of GRK2 protein; [Phenylephrine co-treated with ADRA1B protein] results in increased expression of NPPA protein
4-Aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine]; ADRA1B protein affects the reaction [Phenylephrine results in decreased activity of TGM2 protein]; chlorethylclonidine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine]; Estradiol promotes the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine]
Phenylephrine results in decreased expression of ADRA1B mRNA; Phenylephrine results in decreased expression of ADRA1B protein
Phenylephrine results in increased activity of ADRA1B protein
[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein; [Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein; [Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]

PMID:10801782 PMID:11499749 PMID:11693201 PMID:15306222 PMID:16498073 More...

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 1D

affects response to substance
increases activity
affects binding
multiple interactions
increases response to substance

ADRA1D protein affects the susceptibility to Phenylephrine
Phenylephrine results in increased activity of ADRA1D protein
Phenylephrine binds to ADRA1D protein
[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein; [Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein; [Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; Phentolamine inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]
BMY 7378 inhibits the reaction [ADRA1D protein results in increased susceptibility to Phenylephrine]; Phenylephrine binds to and results in increased activity of ADRA1D protein
ADRA1D affects the susceptibility to Phenylephrine

PMID:8183249 PMID:11901185 PMID:15306222 PMID:15493479 PMID:16371063 More...

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor alpha 2A

multiple interactions

Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]; Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]; Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]]; Yohimbine inhibits the reaction [Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]]

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor alpha 2B

affects response to substance
multiple interactions

ADRA2B protein affects the susceptibility to Phenylephrine
ADRA2B protein affects the susceptibility to [Phenylephrine co-treated with Acetylcholine]

NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355

G

adrenoceptor beta 2

multiple interactions

[Fenoterol binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine; CGP 20712A inhibits the reaction [[Fenoterol binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine]; CGP 20712A inhibits the reaction [[Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine]; CGP 20712A inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine]; Pertussis Toxin promotes the reaction [[Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine]; Pertussis Toxin promotes the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased susceptibility to Phenylephrine]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
increases response to substance

amibegron inhibits the reaction [ADRB3 protein results in increased susceptibility to Phenylephrine]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

angiotensinogen

affects response to substance
increases response to substance
multiple interactions
increases expression

AGT protein affects the susceptibility to Phenylephrine
AGT protein modified form results in increased susceptibility to Phenylephrine
AGT protein modified form promotes the reaction [Phenylephrine results in increased abundance of Inositol Phosphates]; carvedilol inhibits the reaction [AGT protein modified form promotes the reaction [Phenylephrine results in increased abundance of Inositol Phosphates]]; carvedilol inhibits the reaction [AGT protein modified form results in increased susceptibility to Phenylephrine]; irbesartan inhibits the reaction [AGT protein modified form results in increased susceptibility to Phenylephrine]
Phenylephrine results in increased expression of AGT mRNA; Phenylephrine results in increased expression of AGT protein
[Phenylephrine results in increased expression of AGT protein] which results in increased activity of MMP2 protein; AGT protein promotes the reaction [Phenylephrine results in increased expression of FOS mRNA]; Losartan inhibits the reaction [[Phenylephrine results in increased expression of AGT protein] which results in increased activity of MMP2 protein]; PRKCZ protein affects the reaction [Phenylephrine results in increased expression of AGT mRNA]

PMID:2298476 PMID:7900855 PMID:16251426 PMID:16794485 PMID:27094369

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 2

multiple interactions
affects response to substance

[CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [PD 123319 binds to and results in decreased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine
AGTR2 protein affects the susceptibility to Phenylephrine

PMID:11714657 PMID:19151255

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

apoptosis inducing factor, mitochondria associated 1

increases expression

Phenylephrine results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

adenylate kinase 4

increases expression

Phenylephrine results in increased expression of AK4 mRNA

NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
affects phosphorylation

Cyclosporine inhibits the reaction [Phenylephrine results in increased phosphorylation of AKT1 protein]
GRK2 protein affects the reaction [Phenylephrine results in increased phosphorylation of AKT1 protein]
Phenylephrine affects the phosphorylation of AKT1 protein

PMID:10679475 PMID:18084315 PMID:28759639

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 18 family, member A1

increases expression

Phenylephrine results in increased expression of ALDH18A1 mRNA

NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890

G

angiopoietin 1

multiple interactions
increases expression

ANGPT1 protein inhibits the reaction [Phenylephrine results in increased expression of ACTA1 mRNA]; ANGPT1 protein inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA]; ANGPT1 protein inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; ANGPT1 protein inhibits the reaction [Phenylephrine results in increased expression of NPPB mRNA]; Phenylephrine affects the reaction [ANGPT1 protein results in increased expression of ILK protein]
Phenylephrine results in increased expression of ANGPT1 mRNA; Phenylephrine results in increased expression of ANGPT1 protein

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin-like 4

decreases expression

Phenylephrine results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

apolipoprotein E

affects response to substance

APOE protein affects the susceptibility to Phenylephrine

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amphiregulin

increases expression

Phenylephrine results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

Rho guanine nucleotide exchange factor 12

decreases expression

Phenylephrine results in decreased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

arrestin domain containing 3

decreases expression

Phenylephrine results in decreased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

ankyrin repeat and SOCS box-containing 18

decreases expression

Phenylephrine results in decreased expression of ASB18 mRNA

NCBI chr 9:90,531,350...90,595,953
Ensembl chr 9:90,531,596...90,595,848

G

ankyrin repeat and SOCS box-containing 4

increases expression

Phenylephrine results in increased expression of ASB4 mRNA

NCBI chr 4:33,506,992...33,544,630
Ensembl chr 4:33,506,992...33,544,630

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Phenylephrine results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

activating transcription factor 5

increases expression

Phenylephrine results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

ATPase Na+/K+ transporting subunit beta 1

increases expression

Phenylephrine results in increased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions
decreases expression
affects response to substance
increases expression
decreases activity

[Phenylephrine co-treated with ADRA1B protein] results in decreased expression of ATP2A2 protein
Phenylephrine results in decreased expression of ATP2A2 mRNA; Phenylephrine results in decreased expression of ATP2A2 protein
(+)-JQ1 compound inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Phenylephrine results in increased expression of ATP2A2 protein]; [[Phenylephrine results in increased activity of SLC9A1 protein] which results in increased transport of Calcium] which results in increased expression of ATP2A2 protein; [Phenylephrine results in decreased expression of ATP2A2 protein] which results in decreased transport of Calcium; Prazosin inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]; THRB protein affects the reaction [Phenylephrine results in decreased expression of ATP2A2 protein]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]
ATP2A2 protein affects the susceptibility to Phenylephrine
Phenylephrine results in increased expression of ATP2A2 mRNA
Phenylephrine results in decreased activity of ATP2A2 protein

PMID:11499749 PMID:11577024 PMID:15795322 PMID:16236312 PMID:17287366 More...

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATPase plasma membrane Ca2+ transporting 4

increases response to substance

ATP2B4 protein results in increased susceptibility to Phenylephrine

NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246

G

ATPase phospholipid transporting 9A (putative)

increases expression

Phenylephrine results in increased expression of ATP9A mRNA

NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818

G

ataxin 1

multiple interactions

Phenylephrine inhibits the reaction [Iodine-131 inhibits the reaction [PAFAH1B1 protein binds to ATXN1 protein]]

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

activator of transcription and developmental regulator AUTS2

decreases expression

Phenylephrine results in decreased expression of AUTS2 mRNA

NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416

G

arginine vasopressin

multiple interactions
increases secretion

Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dexamethasone inhibits the reaction [Phenylephrine results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]

PMID:2271928 PMID:11102496

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

arginine vasopressin-induced 1

increases expression

Phenylephrine results in increased expression of AVPI1 mRNA

NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154

G

BCL2-associated agonist of cell death

increases expression

Phenylephrine results in increased expression of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BMP and activin membrane-bound inhibitor

increases expression

Phenylephrine results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BCL2 associated X, apoptosis regulator

decreases expression
increases expression
multiple interactions

Phenylephrine results in decreased expression of BAX protein
Phenylephrine results in increased expression of BAX protein
PTHLH protein affects the reaction [Phenylephrine results in decreased expression of BAX protein]

PMID:19910689 PMID:31605733

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCAR1 scaffold protein, Cas family member

multiple interactions
increases phosphorylation

ABL1 protein affects the reaction [Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]]; ABL1 protein affects the reaction [Phenylephrine results in increased phosphorylation of BCAR1 protein]; Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]

NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907

G

branched chain keto acid dehydrogenase E1 subunit alpha

decreases expression

Phenylephrine results in decreased expression of BCKDHA mRNA

NCBI chr 1:81,138,946...81,167,765
Ensembl chr 1:81,138,947...81,167,862

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

BCL2 protein affects the reaction [Phenylephrine results in increased expression of TIMP1 protein]; Phenylephrine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 mRNA]; Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]; PTHLH protein affects the reaction [Phenylephrine results in increased expression of BCL2 mRNA]; PTHLH protein affects the reaction [Phenylephrine results in increased expression of BCL2 protein]
Phenylephrine results in decreased expression of BCL2 protein
Phenylephrine results in increased expression of BCL2 mRNA; Phenylephrine results in increased expression of BCL2 protein

PMID:11042672 PMID:19910689 PMID:31605733 PMID:35979984

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

Phenylephrine inhibits the reaction [Doxorubicin results in decreased expression of BCL2L1 mRNA]; Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2L1 mRNA]; Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2L1 protein]
Phenylephrine results in decreased expression of BCL2L1 protein

PMID:11042672 PMID:31605733 PMID:35979984

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

3-hydroxybutyrate dehydrogenase 1

increases expression

Phenylephrine results in increased expression of BDH1 mRNA

NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671

G

3-hydroxybutyrate dehydrogenase 2

decreases expression

Phenylephrine results in decreased expression of BDH2 mRNA

NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072

G

bradykinin receptor B2

affects response to substance
increases expression

BDKRB2 affects the susceptibility to Phenylephrine
Phenylephrine results in increased expression of BDKRB2 mRNA

PMID:10614985 PMID:18158353

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

brain-derived neurotrophic factor

increases expression

Phenylephrine results in increased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bone morphogenetic protein 2

increases expression

phenylephrine increases expression of mRNA in neonatal rat cardiomyocytes

RGD

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

increases expression

phenylephrine increases expression of mRNA in neonatal rat cardiomyocytes

RGD

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

bone morphogenetic protein 7

decreases expression
increases expression

Phenylephrine results in decreased expression of BMP7 mRNA
phenylephrine increases expression of mRNA in neonatal rat cardiomyocytes

CTD
RGD

PMID:18158353 PMID:26873969

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

BCL2 interacting protein 3 like

increases expression

Phenylephrine results in increased expression of BNIP3L mRNA

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

boule homolog, RNA binding protein

decreases expression

Phenylephrine results in decreased expression of BOLL mRNA

NCBI chr 9:56,734,890...56,859,917
Ensembl chr 9:56,733,584...56,859,916

G

bromodomain containing 4

multiple interactions
increases expression

Phenylephrine promotes the reaction [BRD4 protein binds to NPPA promoter]
Phenylephrine results in increased expression of BRD4 protein

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

BTG anti-proliferation factor 3

increases expression

Phenylephrine results in increased expression of BTG3 mRNA

NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170

G

calcineurin binding protein 1

multiple interactions

CABIN1 protein inhibits the reaction [Phenylephrine results in increased activity of PPP3CB protein]; CABIN1 protein inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; CABIN1 protein inhibits the reaction [Phenylephrine results in increased expression of NPPA protein]; CABIN1 protein promotes the reaction [Phenylephrine results in decreased expression of KCND2 mRNA]; CABIN1 protein promotes the reaction [Phenylephrine results in decreased expression of KCND2 protein]

PMID:10655507 PMID:17060317

NCBI chr20:12,893,314...13,015,357
Ensembl chr20:12,893,358...13,015,357

G

calcium dependent secretion activator

decreases expression

Phenylephrine results in decreased expression of CADPS mRNA

NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779

G

calcitonin-related polypeptide alpha

affects response to substance

CALCA protein affects the susceptibility to Phenylephrine

PMID:11728430 PMID:18055875

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcitonin receptor like receptor

multiple interactions

[Phenylephrine co-treated with Isoproterenol] results in increased expression of CALCRL mRNA

NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910

G

calcium/calmodulin-dependent protein kinase II alpha

decreases expression

Phenylephrine results in decreased expression of CAMK2A mRNA

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions

CAMK2D protein promotes the reaction [Phenylephrine results in increased activity of MAP3K5 protein]

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

carbonic anhydrase 1

decreases activity

Phenylephrine results in decreased activity of CA1 protein

NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208

G

carbonic anhydrase 2

increases expression
decreases activity

Phenylephrine results in increased expression of CAR2 mRNA; Phenylephrine results in increased expression of CAR2 protein
Phenylephrine results in decreased activity of CA2 protein

PMID:17124262 PMID:28800181

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

carbonic anhydrase 4

increases expression

Phenylephrine results in increased expression of CA4 protein

NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501

G

caspase 2

affects activity

Phenylephrine affects the activity of CASP2 protein

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

multiple interactions
increases activity

Phenylephrine inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein]
Phenylephrine results in increased activity of CASP3 protein

PMID:11042672 PMID:31605733

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

affects activity

Phenylephrine affects the activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

Phenylephrine results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calcium-sensing receptor

multiple interactions

Phenylephrine inhibits the reaction [Spermine binds to and results in increased activity of CASR protein]

NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811

G

catalase

multiple interactions
decreases expression

CAT protein inhibits the reaction [Phenylephrine results in decreased expression of MFN2 protein]; CAT protein inhibits the reaction [Phenylephrine results in increased expression of DNM1L protein]; CAT protein inhibits the reaction [Phenylephrine results in increased expression of FIS1 protein]; CAT protein inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CAT protein inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Phenylephrine results in decreased expression of CAT protein

PMID:16513848 PMID:18171680 PMID:20886221

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

multiple interactions

Sodium, Dietary affects the reaction [CAV1 protein results in increased susceptibility to Phenylephrine]

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolin 3

multiple interactions
increases expression
decreases response to substance
affects localization

CAV3 protein inhibits the reaction [Phenylephrine results in increased expression of MYH7 protein]; CAV3 protein inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; CAV3 protein inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Phenylephrine results in increased expression of CAV3 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Phenylephrine results in increased expression of CAV3 protein]; Cyclosporine inhibits the reaction [Phenylephrine results in increased expression of CAV3 mRNA]; Cyclosporine inhibits the reaction [Phenylephrine results in increased expression of CAV3 protein]; KN 62 inhibits the reaction [Phenylephrine results in increased expression of CAV3 mRNA]; KN 62 inhibits the reaction [Phenylephrine results in increased expression of CAV3 protein]
Phenylephrine results in increased expression of CAV3 mRNA; Phenylephrine results in increased expression of CAV3 protein
CAV3 protein results in decreased susceptibility to Phenylephrine
Phenylephrine affects the localization of CAV3 protein

PMID:12847114 PMID:15725944 PMID:19299911

NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid inhibits the reaction [Phenylephrine results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Phenylephrine results in increased expression of CCL2 mRNA]
Phenylephrine results in increased expression of CCL2 mRNA; Phenylephrine results in increased expression of CCL2 protein

PMID:15721863 PMID:15728586

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 27

increases expression

Phenylephrine results in increased expression of CCL27 mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

cellular communication network factor 1

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased expression of CCN1 mRNA]; calphostin C inhibits the reaction [Phenylephrine results in increased expression of CCN1 mRNA]; chelerythrine inhibits the reaction [Phenylephrine results in increased expression of CCN1 mRNA]
Phenylephrine results in increased expression of CCN1 mRNA; Phenylephrine results in increased expression of CCN1 protein

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

increases expression

Phenylephrine results in increased expression of CCN2 mRNA; Phenylephrine results in increased expression of CCN2 protein

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin D1

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased expression of CCND1 protein]

PMID:12163013 PMID:15603588

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

increases expression

Phenylephrine results in increased expression of CCND2 protein

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased expression of CCND3 protein]

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin T1

multiple interactions

Phenylephrine inhibits the reaction [HEXIM1 protein binds to CCNT1 protein]

NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871

G

Cd200 molecule

decreases expression

Phenylephrine results in decreased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

cadherin 2

increases expression

Phenylephrine results in increased expression of CDH2 protein

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin dependent kinase 2

increases expression

Phenylephrine results in increased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

increases expression

Phenylephrine results in increased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
increases stability

Phenylephrine results in increased expression of CDKN1A mRNA; Phenylephrine results in increased expression of CDKN1A protein
Phenylephrine results in increased stability of CDKN1A mRNA

PMID:10766810 PMID:15603588

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Phenylephrine results in increased expression of CDKN1B

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

decreases expression

Phenylephrine results in decreased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CF transmembrane conductance regulator

multiple interactions

[Phenylephrine co-treated with 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride] results in increased activity of CFTR protein; [Phenylephrine co-treated with 6-hydroxy-10-chlorobenzo(c)quinolizinium] results in increased activity of CFTR protein; Glyburide inhibits the reaction [[Phenylephrine co-treated with 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride] results in increased activity of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

coiled-coil-helix-coiled-coil-helix domain containing 6

increases expression

Phenylephrine results in increased expression of CHCHD6 mRNA

NCBI chr 4:121,803,501...122,024,209
Ensembl chr 4:121,792,717...122,024,216

G

chloride intracellular channel 2

decreases expression

Phenylephrine results in decreased expression of CLIC2 mRNA

NCBI chr20:149,337...164,375
Ensembl chr20:148,907...164,355

G

chloride intracellular channel 4

increases expression

Phenylephrine results in increased expression of CLIC4 mRNA

NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452

G

clusterin

increases expression

Phenylephrine results in increased expression of CLU mRNA; Phenylephrine results in increased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

calponin 1

increases expression

Phenylephrine results in increased expression of CNN1 mRNA

NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098

G

collagen type XVIII alpha 1 chain

decreases expression

Phenylephrine results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collectin sub-family member 12

decreases expression

Phenylephrine results in decreased expression of COLEC12 mRNA

NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618

G

corin, serine peptidase

increases expression

Phenylephrine results in increased expression of CORIN mRNA

NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503

G

cytochrome c oxidase copper chaperone COX11

decreases expression
multiple interactions

Phenylephrine results in decreased expression of COX11 protein
Copper Sulfate inhibits the reaction [Phenylephrine results in decreased expression of COX11 protein]; periodate-oxidized adenosine inhibits the reaction [Phenylephrine results in decreased expression of COX11 protein]; VEGFA protein inhibits the reaction [Phenylephrine results in decreased expression of COX11 protein]

PMID:23818984 PMID:25107896

NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322

G

cytochrome c oxidase copper chaperone COX17

multiple interactions
decreases expression

Copper Sulfate inhibits the reaction [Phenylephrine results in decreased expression of COX17 protein]; periodate-oxidized adenosine inhibits the reaction [Phenylephrine results in decreased expression of COX17 protein]; VEGFA protein inhibits the reaction [Phenylephrine results in decreased expression of COX17 protein]

PMID:23818984 PMID:25107896

NCBI chr11:62,400,733...62,406,507

G

cytochrome c oxidase subunit 4i1

decreases expression
multiple interactions

Phenylephrine results in decreased expression of COX4I1 protein
Copper Sulfate inhibits the reaction [Phenylephrine results in decreased expression of COX4I1 protein]; periodate-oxidized adenosine inhibits the reaction [Phenylephrine results in decreased expression of COX4I1 protein]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

carnitine palmitoyltransferase 1B

multiple interactions
decreases expression
increases expression

4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid inhibits the reaction [Phenylephrine results in decreased expression of CPT1B mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B protein]; dorsomorphin promotes the reaction [Phenylephrine results in decreased expression of CPT1B mRNA]; dorsomorphin promotes the reaction [Phenylephrine results in decreased expression of CPT1B protein]
Phenylephrine results in decreased expression of CPT1B mRNA; Phenylephrine results in decreased expression of CPT1B protein
Phenylephrine results in increased expression of CPT1B mRNA

PMID:11879187 PMID:15721863 PMID:19699196

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

cAMP responsive element binding protein 1

multiple interactions

adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; Phenylephrine promotes the reaction [CREB1 protein binds to CREBBP protein]; Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein; Prazosin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; Propranolol inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; Ro 31-8220 inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; RPS6KA5 protein inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]

PMID:14741741 PMID:15522277

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

multiple interactions
increases response to substance

[Phenylephrine results in increased activity of CREBBP protein] which results in increased expression of NPPA protein; CREBBP protein affects the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Phenylephrine promotes the reaction [CREB1 protein binds to CREBBP protein]; Phenylephrine promotes the reaction [NR3C2 protein binds to CREBBP protein]; Phenylephrine results in increased expression of and results in increased localization of CREBBP protein; Phenylephrine results in increased phosphorylation of and results in increased activity of CREBBP protein
CREBBP protein results in increased susceptibility to Phenylephrine

PMID:11705990 PMID:12477714 PMID:15006641 PMID:15522277 PMID:19966502

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cAMP responsive element modulator

increases expression

Phenylephrine results in increased expression of CREM mRNA

PMID:12791704 PMID:18158353

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

CRK proto-oncogene, adaptor protein

multiple interactions

ABL1 protein affects the reaction [Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]]; ABL1 protein affects the reaction [Phenylephrine promotes the reaction [CRK protein binds to WASL protein]]; Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

casein kinase 2 alpha 1

decreases expression

Phenylephrine results in decreased expression of CSNK2A1 mRNA

NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696

G

chondroitin sulfate proteoglycan 4

increases expression

Phenylephrine results in increased expression of CSPG4 mRNA

NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010

G

cysteine and glycine-rich protein 2

increases expression

Phenylephrine results in increased expression of CSRP2 mRNA

NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745

G

cysteine and glycine rich protein 3

increases localization

Phenylephrine results in increased localization of CSRP3 protein

NCBI chr 1:98,528,067...98,546,647
Ensembl chr 1:98,528,068...98,546,653

G

cystathionine gamma-lyase

increases activity

Phenylephrine results in increased activity of CTH protein

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

catenin beta 1

multiple interactions

Phenylephrine promotes the reaction [CTNNB1 protein binds to NPPA promoter]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin C

decreases expression

Phenylephrine results in decreased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

C-X-C motif chemokine ligand 1

decreases expression

Phenylephrine results in decreased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

decreases expression

Phenylephrine results in decreased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

decreases expression

Phenylephrine results in decreased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

CXXC finger protein 4

decreases expression

Phenylephrine results in decreased expression of CXXC4 mRNA

NCBI chr 2:222,664,148...222,689,365
Ensembl chr 2:222,664,771...222,689,365

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases expression

Phenylephrine results in increased expression of CYP11B2 mRNA

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Phenylephrine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]; Phenylephrine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 protein]; Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 26, subfamily b, polypeptide 1

increases expression

Phenylephrine results in increased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 4, subfamily a, polypeptide 1

multiple interactions
increases response to substance
affects response to substance

20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]; DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]

PMID:11124159 PMID:12388396

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 51

increases expression

Phenylephrine results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

death associated protein kinase 1

decreases expression

Phenylephrine results in decreased expression of DAPK1 mRNA

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

diacylglycerol kinase epsilon

multiple interactions

DGKE protein inhibits the reaction [Phenylephrine results in increased abundance of Diglycerides]; DGKE protein inhibits the reaction [Phenylephrine results in increased localization of PRKCA protein]; DGKE protein inhibits the reaction [Phenylephrine results in increased localization of PRKCE protein]

NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100

G

diacylglycerol kinase zeta

multiple interactions

DGKZ protein inhibits the reaction [Phenylephrine results in increased abundance of Diglycerides]; DGKZ protein inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]

NCBI chr 3:77,904,149...77,946,114
Ensembl chr 3:77,904,150...77,946,099

G

7-dehydrocholesterol reductase

increases expression

Phenylephrine results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

iodothyronine deiodinase 2

increases activity
increases expression

Phenylephrine results in increased activity of DIO2 protein
Phenylephrine results in increased expression of DIO2 mRNA

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,